Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer
2011 · British Journal of Cancer · 107 citations
https://doi.org/10.1038/bjc.2011.348
H
Hiroyasu Kaneda
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
253
Papers
5.9K
Citations
35
h-index
68
i10-index
Hiroyasu Kaneda is an academic researcher from Osaka Metropolitan University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 35, co-authored 216 publications.
ORCID: 0000-0002-7696-2391Papers by this author
worksSwitching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure
2011 · Biochemical and Biophysical Research Communications · 53 citations
https://doi.org/10.1016/j.bbrc.2011.03.002
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer
2009 · Investigational New Drugs · 44 citations
https://doi.org/10.1007/s10637-009-9321-x
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
2014 · Investigational New Drugs · 43 citations
https://doi.org/10.1007/s10637-014-0196-0
Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer
2004 · British Journal of Cancer · 21 citations
https://doi.org/10.1038/sj.bjc.6601817
Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations
2021 · Translational Oncology · 15 citations
https://doi.org/10.1016/j.tranon.2021.101102
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat